Management Team

Richard Marshak, CEO

Richard Marshak, VMD, MBA, is the Chief Executive Officer of Mount Tam Biotechnologies. Dr. Marshak possesses 18 years of pharmaceutical experience across a wide range of leadership roles, touching virtually all aspects of drug development and commercialization.

While at Abbott/Abbvie, Dr. Marshak occupied roles of increasing responsibility spanning marketing, business development, strategic planning and general management in the Pharmaceutical Products Group. These included marketing roles in the Virology and Cardiovascular Franchises, Director of Marketing for Synthroid, General Manager Pain Care, General Manager Alliance Management and Strategic Planning and Senior Director of Strategic Pricing. Since leaving Abbvie, Dr. Marshak has served as strategic consultant to a range of companies, helping to guide critical decisions including product development, corporate development and commercialization strategies. Prior to his work in the pharmaceutical industry Dr. Marshak spent time as an equine veterinarian in Pennsylvania.

Dr. Marshak holds VMD and BA degrees from the University of Pennsylvania and an MBA from the University of Chicago’s Booth School of Business.

Timothy Powers, Chief Scientific Officer

Timothy Powers, PhD, is the Chief Scientific Officer of Mount Tam Biotechnologies. Dr. Powers has been engaged in all aspects of drug discovery and development for more than 20 years at both small and large biotechnology and pharmaceutical companies.

Most recently, Dr. Powers held the position of Scientific Director of Medicinal Chemistry at Amgen where he provided scientific and executive leadership to the teams that were responsible for the discovery and development of Amgen’s first ß-secretase small-molecule clinical candidate for Alzheimer’s disease. Prior to joining Amgen, he was Director of Medicinal Chemistry at Alantos Pharmaceuticals, overseeing all aspects of the company’s discovery research activities which led to the clinical development of the company’s two flagship programs in the areas of type-II diabetes and osteoarthritis. Alantos was purchased by Amgen for $300M, and Dr. Powers was integral to the transaction.

Dr. Powers has authored over 50 publications and scientific presentations and is an inventor on over 40 issued U.S. patents and patent applications in the areas of drug discovery and process manufacturing spanning therapeutic disease areas of inflammation, neuroscience, oncology and metabolic diseases. He holds a B.S. degree in Chemistry from the University of California, Davis and received his Ph.D. in Organic Chemistry from the University of Chicago.

James Stapleton, Chief Financial Officer

Mr. Stapleton joined Mount Tam Biotechnologies in May 2016. Mr. Stapleton brings over 25 years of financial and operating experience, achieving his first CFO position at a public company in 1987. Currently, Mr. Stapleton is a director, and Audit Committee chair for Summer Energy Holdings (OTC BB SUME). From August 2012 to May 2014 Mr. Stapleton was the CFO of Ozone International, LLC, which provides ozone equipment and solutions to food processors. From February 2012 to June 2012, Mr. Stapleton was the CFO for Jones Soda (OTC BB JSDA). From 2007 to 2011, Mr. Stapleton was a consultant and advisor to a variety of companies. From May 2005 through July 2007, Mr. Stapleton was the Chief Financial Officer of Bionovo (OTC BB BNVI). From January 2003 through April 2005, Mr. Stapleton was the Chief Financial Officer of Auxilio (OTC BB AUXO). . Mr. Stapleton graduated from the University of California at Irvine (UCI) with a MBA in 1995, and from the University of Washington with a BA in Economics in 1985.

Copyright © 2017 / All rights reserved.Mount Tam Biomedical / Notices & Disclaimers